Skip to contents
Elizabeth W. Loder, MD
Associate Neurologist, Brigham and Women's Hospital
Professor of Neurology, Harvard Medical School

Brigham and Women's Hospital
Department of Neurology
75 Francis Street
Boston, MA 02115

Edit Profile


Publications (Pulled from Harvard Catalyst Profiles):

1. Gelfand AA, Loder E. Potential Benefits of Migraine-What Is It Good For? JAMA Neurol. 2019 Mar 01; 76(3):250-251.

2. Loder E, Renthal W. Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. JAMA Intern Med. 2019 Mar 01; 179(3):421-422.

3. Loder EW, Burch RC. Consideration of Costs and Open-Label Studies of Erenumab-Reply. JAMA Neurol. 2019 Feb 01; 76(2):236-237.

4. Tfelt-Hansen P, Loder E. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful? Headache. 2019 Jan; 59(1):113-117.

5. Loder EW, Rayhill M, Burch RC. Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Headache. 2018 Nov; 58(10):1639-1657.

6. Loder EW, Burch RC. Who Should Try New Antibody Treatments for Migraine? JAMA Neurol. 2018 Sep 01; 75(9):1039-1040.

7. Loder E, Rizzoli P. Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. Headache. 2018 Nov; 58 Suppl 3:218-229.

8. Merino JG, Loder E, Abbasi K. What readers thought about a research paper's approach to compare treatment effects on mortality. BMJ. 2018 Aug 17; 362:k3213.

9. Loder E, Weizenbaum E, Giddon D. Migraine Pain Location and Measures of Healthcare Use and Distress: An Observational Study. Pain Res Manag. 2018; 2018:6157982.

10. Loder EW, Robbins MS. Monoclonal Antibodies for Migraine Prevention: Progress, but Not a Panacea. JAMA. 2018 05 15; 319(19):1985-1987.